• Recon: Alexion to Acquire Achillion for $930M; Lilly's Pancreatic Cancer Drug Fails in Phase III Trial

    Recon: Alexion to Acquire Achillion for $930M; Lilly’s Pancreatic Cancer Drug … Alexion acquiring Achillion to expand reach into rare, immune-related …

    Read More
  • 0 0